Table 1.

Comparison of cerebral hAβ levels in vehicle-treated and 1,25(OH)₂D₃-treated Tg mice

Vehicle or 1,25(OH)₂D₃ treatment (μg/kg, i.p.)	Soluble Aβ concentration in brain (ng/g wet weight)			Insoluble Aβ concentration in brain (ng/g wet weight)
Vehicle or 1,25(OH)₂D₃ treatment (μg/kg, i.p.)	hAβ_1–40	hAβ_1–42	hAβ_1–42/hAβ_1–40 ratio	hAβ_1–40	hAβ_1–42	hAβ_1–42/hAβ_1–40 ratio
Tg2576 (5 males per group), began treatment at 10 weeks old, 11 weeks old when killed
0 (q2d × 4)	39.1 ± 4.25	11.1 ± 0.240	0.276 ± 0.0169	NP^b	NP	NP
2.5 (q2d × 4)	15.4 ± 2.15^*	5.82 ± 0.891^*	0.357 ± 0.0226	NP	NP	NP
TgCRND8 (4 males, 3–4 females per group), began treatment at 9 weeks old, 17 weeks old when killed
0 (q3d × 19)	872 ± 33.7	3360 ± 122	3.65 ± 0.176	923 ± 66.7	4640 ± 143	4.75 ± 0.247
2.5 (q3d × 19)	618 ± 18.7^*	2240 ± 153^*	3.39 ± 0.196	514 ± 69.0^*	3870 ± 133^*	7.16 ± 0.361^*
TgCRND8 (4 females per group), began treatment at 20 weeks old, 21 weeks old when killed
0 (q2d × 4)	1060 ± 25.9	2920 ± 202	2.78 ± 0.219	3850 ± 931	18000 ± 1700	3.83 ± 0.166
2.5 (q2d × 4)	675 ± 54.3^**	1970 ± 130^**	3.04 ± 0.417	4710 ± 282	16500 ± 878	3.54 ± 0.312
2.5 (q2d × 4) + 10 mg/kg elacridar (q12h × 8)	1240 ± 27.6^***	4700 ± 214^***	3.78 ± 0.107^***	6030 ± 238	20400 ± 443	3.40 ± 0.198

hAβ levels were not detected in non-Tg mice. NP, Not present.
↵*p < 0.05 for 1,25(OH)₂D₃ treatment compared with vehicle treatment, Student's two-tailed t test.
↵**p < 0.05 for 1,25(OH)₂D₃ treatment compared with vehicle treatment, one-way ANOVA with Bonferroni's multiple comparisons test.
↵***p < 0.05 for elacridar plus 1,25(OH)2D3 treatment compared with vehicle treatment, one-way ANOVA with Bonferroni's multiple comparisons test.